Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers

Yoshikawa,Tomoyuki; Miyamoto,Morikazu; Aoyama,Tadashi; Matsuura,Hiroko; Iwahashi,Hideki; Ishibashi,Hiroki; Kakimoto,Soichiro; Sakamoto,Takahiro; Takasaki,Kazuki; Suminokura,Jin; Tsuda,Hitoshi; Kawaguchi,Hiroyuki; Yoshino,Aihide; Takano,Masashi

doi:10.3892/mco.2021.2339

Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers

Authors:
- Tomoyuki Yoshikawa
- Morikazu Miyamoto
- Tadashi Aoyama
- Hiroko Matsuura
- Hideki Iwahashi
- Hiroki Ishibashi
- Soichiro Kakimoto
- Takahiro Sakamoto
- Kazuki Takasaki
- Jin Suminokura
- Hitoshi Tsuda
- Hiroyuki Kawaguchi
- Aihide Yoshino
- Masashi Takano
View Affiliations

Affiliations: Division of Palliative Care, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan, Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan, Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan, Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan
Published online on: July 1, 2021 https://doi.org/10.3892/mco.2021.2339
Article Number: 177
Copyright: © Yoshikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Almost a quarter of a century has passed since the term sarcopenia was defined. Sarcopenia is recognized as a poor prognostic factor in a variety of cancer types. In ovarian cancer, it remains controversial whether sarcopenia affects prognosis and how it should be evaluated. The present study aimed to evaluate the association between the volume of the psoas major muscle and survival in patients with epithelial ovarian cancer. Medical charts of patients with epithelial ovarian cancer who received first‑line chemotherapy with paclitaxel and carboplatin at the National Defense Medical College Hospital (Tokorozawa, Japan) between April 2010 and January 2015 were retrospectively reviewed. The bilateral psoas major muscle areas at the fifth lumbar vertebra were measured using computed tomography images. The Institutional Review Board at National Defense Medical College Hospital (Tokorozawa, Japan) approved the study protocol. A total of 72 patients with epithelial ovarian cancer who received combination therapy with paclitaxel and carboplatin were identified and enrolled. The median psoas muscle index (PMI; psoas muscle major cross‑sectional area divided by height squared) was 5.4 cm²/m² (range, 3.3‑10.0). Patients with higher PMI had significantly improved overall survival (OS) compared with those with lower PMI [log‑rank test P=0.014; hazard ratio (HR), 2.61; 95% confidence interval (CI), 1.21‑6.06]. Multivariate analysis for OS revealed that lower PMI was an independent unfavorable prognostic factor (HR, 3.87; 95% CI, 1.37‑12.1; P=0.0098). The volume of psoas major muscle mass could be a potential biomarker for prognosis in patients with epithelial ovarian cancer.

View Figures

View References

1	Evans WJ and Campbell WW: Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 123 (Suppl 2):S465–S468. 1993.PubMed/NCBI View Article : Google Scholar
2	Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla Ē and Prado CM: Cancer-associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc Nutr Soc. 75:199–211. 2016.PubMed/NCBI View Article : Google Scholar
3	Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ and Lindeman RD: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 147:755–763. 1998.PubMed/NCBI View Article : Google Scholar
4	Shachar SS, Williams GR, Muss HB and Nishijima TF: Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 57:58–67. 2016.PubMed/NCBI View Article : Google Scholar
5	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011.PubMed/NCBI View Article : Google Scholar
6	Solheim TS, Fayers PM, Fladvad T, Tan B, Skorpen F, Fearon K, Baracos VE, Klepstad P, Strasser F and Kaasa S: European Palliative Care Research Collaborative (EPCRC) and the European Pharmacogenetic Study (EPOS). Is there a genetic cause of appetite loss?-an explorative study in 1,853 cancer patients. J Cachexia Sarcopenia Muscle. 3:191–198. 2012.PubMed/NCBI View Article : Google Scholar
7	Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, Xiao J, Alexeeff S, Corley D, Weltzien E, et al: Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: Results from the C SCANS study. JAMA Oncol. 3(e172319)2017.PubMed/NCBI View Article : Google Scholar
8	Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW and van Gorp T: Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 7:458–466. 2016.PubMed/NCBI View Article : Google Scholar
9	Kumar A, Moynagh MR, Multinu F, Cliby WA, McGree ME, Weaver AL, Young PM, Bakkum-Gamez JN, Langstraat CL, Dowdy SC, et al: Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. 142:311–316. 2016.PubMed/NCBI View Article : Google Scholar
10	Rutten IJ, Ubachs J, Kruitwagen RF, Beets-Tan RG, Olde Damink SW and Van Gorp T: Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 8:630–638. 2017.PubMed/NCBI View Article : Google Scholar
11	Yoshikawa T, Takano M, Miyamoto M, Yajima I, Shimizu Y, Aizawa Y, Suguchi Y, Moriiwa M, Aoyama T, Soyama H, et al: Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol. 80:555–561. 2017.PubMed/NCBI View Article : Google Scholar
12	Javadi S, Ganeshan DM, Qayyum A, Iyer RB and Bhosale P: Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016.PubMed/NCBI View Article : Google Scholar
13	Conrad LB, Awdeh H, Acosta-Torres S, Conrad SA, Bailey AA, Miller DS and Lea JS: Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer. J Surg Oncol. 117:1020–1028. 2018.PubMed/NCBI View Article : Google Scholar
14	Baracos VE: Psoas as a sentinel muscle for sarcopenia: A flawed premise. J Cachexia Sarcopenia Muscle. 8:527–528. 2017.PubMed/NCBI View Article : Google Scholar
15	Ubachs J, Ziemons J, Minis-Rutten IJ, Kruitwagen RF, Kleijnen J, Lambrechts S, Olde Damink SW, Rensen SS and Van Gorp T: Sarcopenia and ovarian cancer survival: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 10:1165–1174. 2019.PubMed/NCBI View Article : Google Scholar
16	Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, West L, Zhang Y and Gehrig PA: Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 156:695–700. 2020.PubMed/NCBI View Article : Google Scholar
17	Kim SI, Kim TM, Lee M, Kim HS, Chung HH, Cho JY and Song YS: Impact of CT-determined sarcopenia and body composition on survival outcome in patients with advanced-stage high-grade serous ovarian carcinoma. Cancers (Basel). 12(559)2020.PubMed/NCBI View Article : Google Scholar
18	Huang CY, Yang YC, Chen TC, Chen JR, Chen YJ, Wu MH, Jan YT, Chang CL and Lee J: Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. 11:534–546. 2020.PubMed/NCBI View Article : Google Scholar
19	Mintziras I, Miligkos M, Wächter S, Manoharan J, Maurer E and Bartsch DK: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis. Int J Surg. 59:19–26. 2018.PubMed/NCBI View Article : Google Scholar
20	Dutra MT, Avelar BP, Souza VC, Bottaro M, Oliveira RJ, Nóbrega OT and Moreno Lima R: Relationship between sarcopenic obesity-related phenotypes and inflammatory markers in postmenopausal women. Clin Physiol Funct Imaging. 37:205–210. 2017.PubMed/NCBI View Article : Google Scholar
21	Iyengar NM, Gucalp A, Dannenberg AJ and Hudis CA: Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol. 34:4270–4276. 2016.PubMed/NCBI View Article : Google Scholar